Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANAVEX LIFE SCIENCES CORP. Director's Dealing 2024

Dec 24, 2024

32464_dirs_2024-12-23_5c810ba9-8d7b-4c64-afa5-48bbbd16de22.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2024-12-19

Reporting Person: Boenisch Sandra (PFO & Treasurer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-12-19 Stock Option (Right to Buy) $5.36 A 12500 Acquired 2034-02-20 Common Stock (12500) Direct

Footnotes

F1: On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 12,500 shares.